Published • loading... • Updated
Biktarvy Drives Gilead Sciences (GILD) Revenue to $7.8 Billion in Latest Quarter
Summary by Blockonomi
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Gilead Sciences (GILD) Stock Up 35% as HIV Drugs Fuel Growth Streak
TLDR Gilead Sciences stock has gained roughly 35% over the past year, trading recently around $147.82. The company’s HIV drug Biktarvy and newer prophylactic treatment Yeztugo are driving strong revenue growth. Gilead raised its full-year sales guidance to between $30.1 billion and $30.4 billion....
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
